We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed
levodopa pro-drug, and
carbidopa compared with
levodopa and
carbidopa to stabilize
levodopa plasma concentration fluctuations in Japanese patients with
Parkinson's disease. In an open-label two-period design, patients (n = 12) with
Parkinson's disease received
levodopa and
carbidopa for 3 days before 7 days of treatment with ONO-2160 and
carbidopa. Patients were primarily evaluated using the Unified Parkinson's Disease Rating Scale Part III, a
Parkinson's disease symptom diary, and analysis of adverse events. Pharmacokinetic analysis of plasma
levodopa concentration was also performed. ONO-2160 and
carbidopa therapy stabilized effective plasma
levodopa concentration. No adverse events with safety concerns were observed. The combination of ONO-2160 and
carbidopa produced a prolonged and stable plasma
levodopa concentration with a reduction in Unified Parkinson's Disease Rating Scale Part III total scores. The combination was well tolerated, with no safety concerns, when administered to Japanese patients with
Parkinson's disease.